Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 11/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 3/20 | 0.38 |
| ▸ | INSR | P06213 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312921 | 0.91 | ACVRL1 (0.42) | ACVRL1METTNK2IGF1R | |
| SCHEMBL14312981 | 0.90 | ACVRL1 (0.37) | ACVRL1METTNK2IGF1RINSR | |
| SCHEMBL5074844 | 0.89 | ACVRL1 (0.43) | ACVRL1METTNK2IGF1RINSR | |
| Hydrochloric Acid SCHEMBL5081039 | 0.89 | ACVRL1 (0.42) | ACVRL1METTNK2IGF1RINSR | |
| SCHEMBL5077807 | 0.87 | ACVRL1 (0.43) | ACVRL1TNK2IGF1R | |
| SCHEMBL14313047 | 0.87 | ACVRL1 (0.37) | ACVRL1TNK2IGF1RINSR | |
| SCHEMBL14312667 | 0.86 | SRC (0.37) | ACVRL1TNK2 | |
| SCHEMBL14327041 | 0.86 | ACVRL1 (0.49) | ACVRL1METTNK2IGF1RINSR | |
| SCHEMBL14313034 | 0.86 | RIPK1 (0.41) | ACVRL1PIK3CD | |
| SCHEMBL14312999 | 0.85 | ACVRL1 (0.44) | ACVRL1METTNK2IGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |